Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

FDA Supplemental Approval Summary: Lenvatinib for the Treatment of Unresectable Hepatocellular Carcinoma.

Autor: Nair A; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Reece K; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Donoghue MB; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Yuan WV; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Rodriguez L; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Keegan P; Oncology Center for Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA., Pazdur R; Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.; Oncology Center for Excellence, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.

Publikováno v: The oncologist [Oncologist] 2021 Mar; Vol. 26 (3), pp. e484-e491. Date of Electronic Publication: 2020 Nov 10.